Make sure the patient is not pregnant before the administration of Medroxyprogesterone Acetate (DEPOTRUST). The patient should inform the healthcare provider if the patient has the following conditions before the administration of Medroxyprogesterone Acetate (DEPOTRUST): undiagnosed vaginal bleeding; possible pregnancy; history or current high risk of arterial disease; hormone-dependent neoplasms; hepatic impairment especially if severe; porphyria; after recent evacuation of hydatidiform mole.